Skip to content
10-Q

Quarterly Report

Dova Pharmaceuticals Inc.

0001685071-18-000010

← back to feed
Filed
Nov 8, 2018 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2018 · Nov 5, 2018 28.2M sh
Long Term Debt Q3 2018 · Sep 30, 2018 $16.21M
Long Term Debt Q3 2018 · Dec 31, 2017 $0
Short Term Debt Q3 2018 · Sep 30, 2018 $4.17M
Short Term Debt Q3 2018 · Dec 31, 2017 $0
Cash And Equivalents Q3 2018 · Sep 30, 2018 $122.03M
Cash And Equivalents Q3 2018 · Dec 31, 2017 $94.85M
Current Liabilities Q3 2018 · Sep 30, 2018 $17.31M
Current Liabilities Q3 2018 · Dec 31, 2017 $35.2M
Total Liabilities Q3 2018 · Sep 30, 2018 $35.89M
Total Liabilities Q3 2018 · Dec 31, 2017 $35.2M
Current Assets Q3 2018 · Sep 30, 2018 $129.81M
Current Assets Q3 2018 · Dec 31, 2017 $96.32M
Total Assets Q3 2018 · Sep 30, 2018 $130.09M
Total Assets Q3 2018 · Dec 31, 2017 $96.38M
Capex Q3 2018 · Sep 30, 2017 $35K
Operating Cash Flow Q3 2018 · Sep 30, 2017 −$6.26M
Rd Expense restated Q3 2018 · Sep 30, 2017 $5.43M
Rd Expense restated Q3 2018 · Sep 30, 2017 $13M
Net Income Q3 2018 · Sep 30, 2017 −$9.72M
Net Income Q3 2018 · Sep 30, 2017 −$20.65M
Operating Income Q3 2018 · Sep 30, 2017 −$9.61M
Operating Income Q3 2018 · Sep 30, 2017 −$20.04M
Revenue Q3 2018 · Sep 30, 2017 $0
Revenue Q3 2018 · Sep 30, 2017 $0